Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study

被引：1

作者：

Croop, Robert ^{[1
]}

Ailani, Jessica ^{[2
]}

Kudrow, David

Smith, Timothy ^{[3
]}

Lipton, Richard ^{[4
]}

Thiry, Alexandra ^{[1
]}

Jensen, Christopher ^{[1
]}

Kamen, Lisa ^{[1
]}

机构：

[1] Biohaven Pharmaceut, New Haven, CT USA

[2] Medstar Georgetown Neurol, Washington, DC USA

[3] Study Metrix Res, St Petersburg, FL USA

[4] Albert Einstein Coll Med, New York, NY USA

来源：

NEUROLOGY | 2023年 / 100卷 / 17期

关键词：

D O I：

10.1212/WNL.0000000000202051

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P10-12.010

引用

页数：6

共 50 条

[41] Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
Lipton, Richard B.
Tepper, Stewart J.
Silberstein, Stephen D.
Kudrow, David
Ashina, Messoud
Reuter, Uwe
Dodick, David W.
Zhang, Feng
Rippon, Gregory A.
Cheng, Sunfa
Mikol, Daniel D.
CEPHALALGIA, 2021, 41 (01) : 6 - 16
[42] Effectiveness and safety of oxycodone/naloxone controlled release tablets during three 52-week open-label extension studies
Moline, M.
Berger, B.
Dain, B.
Munera, C.
Hopp, M.
Green, I.
JOURNAL OF PAIN, 2014, 15 (04): : S90 - S90
[43] Adalimumab in the treatment of active ankylosing spondylitis: Results of an open-label, 52-week trial
Haibel, H
Brandt, H
Baraliakos, X
Rudwaleit, M
Listing, J
Braun, J
Kupper, H
Sieper, J
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 316 - 316
[44] Randomised, double-blind, phase-2 study and 52-Week interim results of an open-label extension to evaluate AMG334 for the prevention of episodic migraine
Sun, H.
Dodick, D.
Goadsby, P. J.
Silberstein, S.
Reuter, U.
Ashina, M.
Saper, J.
Cady, R.
Zhang, F.
Trotman, M. -L.
Dietrich, J.
Lenz, R.
EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 81 - 81
[45] A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
Bowlus, Christopher L.
Galambos, Michael R.
Aspinall, Richard J.
Hirschfield, Gideon M.
Jones, David E. J.
Doerffel, Yvonne
Gordon, Stuart C.
Harrison, Stephen A.
Kremer, Andreas E.
Mayo, Marlyn J.
Thuluvath, Paul J.
Levy, Cynthia
Swain, Mark G.
Neff, Guy W.
Sheridan, David A.
Stanca, Carmen M.
Berg, Christoph P.
Goel, Aparna
Shiffman, Mitchell L.
Vierling, John M.
Boudes, Pol
Steinberg, Alexandra
Choi, Yun-Jung
McWherter, Charles A.
JOURNAL OF HEPATOLOGY, 2022, 77 (02) : 353 - 364
[46] Symptom stability in de novo and rollover patients with bipolar I disorder receiving aripiprazole once-monthly in a 52-week, open-label study
Calabrese, J.
Madera, J.
Such, P.
Chen, M.
Baker, R.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S29 - S29
[47] Asenapine add-on treatment for schizophrenia adults who received antipsychotics: A 52-week, open-label study
Kishi, Taro
Iwama, Yasuhiro
Sasagawa, Yuji
Hiraoka, Shuichi
Kamei, Aya
Iwata, Nakao
PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2023, 77 (06) : 365 - 366
[48] Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: Results from a randomized, 52-week, open-label study
Yasuda, Hitoshi
Hotta, Nigishi
Kasuga, Masato
Kashiwagi, Atsunori
Kawamori, Ryuzo
Yamada, Tadaaki
Baba, Yuko
Alev, Levent
Nakajo, Ko
JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (01): : 100 - 108
[49] Safety and Tolerability of Aripiprazole for Irritability in Pediatric Patients With Autistic Disorder: A 52-Week, Open-Label, Multicenter Study
Marcus, Ronald N.
Owen, Randall
Manos, George
Mankoski, Raymond
Kamen, Lisa
McQuade, Robert D.
Carson, William H.
Findling, Robert L.
JOURNAL OF CLINICAL PSYCHIATRY, 2011, 72 (09) : 1270 - 1276
[50] A 52-week, open-label, dose-titration safety study of imidapril in the treatment of mild to moderate hypertension
Dews, I
VandenBurg, M
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2001, 62 (02): : 167 - 176

← 1 2 3 4 5 →